Kinnate Biopharma
(NASDAQ:KNTE)
$2.6702
0.0102[0.38%]
Last update: 12:05PM Get Real Time Here
Consensus Rating1
Buy
Highest Price Target1
$32.00
Lowest Price Target1
$2.00
Consensus Price Target1
$10.84

Kinnate Biopharma Stock (NASDAQ:KNTE), Analyst Ratings, Price Targets, Predictions

Kinnate Biopharma Inc has a consensus price target of $10.84, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from Stifel, Wedbush, and Jefferies on February 26, 2024, January 17, 2024, and September 19, 2023. With an average price target of $2.2 between Stifel, Wedbush, and Jefferies, there's an implied -17.73% downside for Kinnate Biopharma Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Jan
1
Feb
0
0
0
0
0
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Stifel
Wedbush
Jefferies
HC Wainwright & Co.
Piper Sandler

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Kinnate Biopharma

date
▲▼
ticker
▲▼
Buy Now
Company
▲▼
Current price
▲▼
Upside/Downside
▲▼
Analyst Firm
▲▼
Analyst & % Accurate
▲▼
Price Target Change
▲▼
Rating Change
▲▼
Previous / Current Rating
▲▼
Get Alert
02/26/2024KNTEBuy Now
Kinnate Biopharma
$2.67-3%Stifel
Benjamin Burnett
$1.5 → $2.59MaintainsHoldGet Alert
01/17/2024KNTEBuy Now
Kinnate Biopharma
$2.67-25.1%Wedbush
David Nierengarten
→ $2ReiteratesNeutral → NeutralGet Alert
09/19/2023KNTEBuy Now
Kinnate Biopharma
$2.67-25.1%Jefferies
Roger Song
$31 → $2MaintainsBuyGet Alert
09/19/2023KNTEBuy Now
Kinnate Biopharma
$2.67-25.1%Wedbush
David Nierengarten
$14 → $2DowngradeOutperform → NeutralGet Alert
09/19/2023KNTEBuy Now
Kinnate Biopharma
$2.67—HC Wainwright & Co.
Robert Burns
—DowngradeBuy → NeutralGet Alert
09/19/2023KNTEBuy Now
Kinnate Biopharma
$2.6749.8%Piper Sandler
Christopher Raymond
$20 → $4DowngradeOverweight → NeutralGet Alert
08/15/2023KNTEBuy Now
Kinnate Biopharma
$2.67798.81%HC Wainwright & Co.
Robert Burns
→ $24ReiteratesBuy → BuyGet Alert
06/08/2023KNTEBuy Now
Kinnate Biopharma
$2.67798.81%HC Wainwright & Co.
Robert Burns
→ $24ReiteratesBuy → BuyGet Alert
05/18/2023KNTEBuy Now
Kinnate Biopharma
$2.67798.81%HC Wainwright & Co.
Robert Burns
$25 → $24MaintainsBuyGet Alert
05/12/2023KNTEBuy Now
Kinnate Biopharma
$2.67424.31%Wedbush
David Nierengarten
→ $14ReiteratesOutperform → OutperformGet Alert
05/12/2023KNTEBuy Now
Kinnate Biopharma
$2.67102.23%Stifel
Benjamin Burnett
$5 → $5.4MaintainsHoldGet Alert
04/20/2023KNTEBuy Now
Kinnate Biopharma
$2.67836.26%HC Wainwright & Co.
Robert Burns
$33 → $25MaintainsBuyGet Alert
04/19/2023KNTEBuy Now
Kinnate Biopharma
$2.67873.71%Goldman Sachs
Paul Choi
$29 → $26MaintainsBuyGet Alert
04/18/2023KNTEBuy Now
Kinnate Biopharma
$2.67873.71%Goldman Sachs
Paul Choi
$29 → $26MaintainsBuyGet Alert
03/20/2023KNTEBuy Now
Kinnate Biopharma
$2.671135.86%HC Wainwright & Co.
Robert Burns
→ $33Reiterates → BuyGet Alert
03/16/2023KNTEBuy Now
Kinnate Biopharma
$2.67199.6%Stifel
Benjamin Burnett
$11 → $8MaintainsHoldGet Alert
03/16/2023KNTEBuy Now
Kinnate Biopharma
$2.67836.26%Wedbush
David Nierengarten
$29 → $25MaintainsOutperformGet Alert
11/17/2022KNTEBuy Now
Kinnate Biopharma
$2.67311.95%Stifel
Benjamin Burnett
$35 → $11DowngradeBuy → HoldGet Alert
07/28/2022KNTEBuy Now
Kinnate Biopharma
$2.671135.86%HC Wainwright & Co.
Robert Burns
→ $33Initiates → BuyGet Alert

FAQ

Q

What is the target price for Kinnate Biopharma (KNTE)?

A

The latest price target for Kinnate Biopharma (NASDAQ: KNTE) was reported by Stifel on February 26, 2024. The analyst firm set a price target for $2.59 expecting KNTE to fall to within 12 months (a possible -3.00% downside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Kinnate Biopharma (KNTE)?

A

The latest analyst rating for Kinnate Biopharma (NASDAQ: KNTE) was provided by Stifel, and Kinnate Biopharma maintained their hold rating.

Q

When was the last upgrade for Kinnate Biopharma (KNTE)?

A

There is no last upgrade for Kinnate Biopharma.

Q

When was the last downgrade for Kinnate Biopharma (KNTE)?

A

The last downgrade for Kinnate Biopharma Inc happened on September 19, 2023 when Wedbush changed their price target from $14 to $2 for Kinnate Biopharma Inc.

Q

When is the next analyst rating going to be posted or updated for Kinnate Biopharma (KNTE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kinnate Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kinnate Biopharma was filed on February 26, 2024 so you should expect the next rating to be made available sometime around February 26, 2025.

Q

Is the Analyst Rating Kinnate Biopharma (KNTE) correct?

A

While ratings are subjective and will change, the latest Kinnate Biopharma (KNTE) rating was a maintained with a price target of $1.50 to $2.59. The current price Kinnate Biopharma (KNTE) is trading at is $2.67, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch